Vigene Biosciences

About:

Vigene develops gene delivery technologies with the mission to advance biomedical research and to make gene therapy affordable.

Website: https://www.vigenebio.com

Twitter/X: VigeneBio

Description:

Vigene develops gene delivery technologies with the mission to advance biomedical research and to make gene therapy affordable. It offers both research-grade and cGMP-grade AAV, lentivirus, and adenovirus-based products and custom services. Some of its product offerings include ready-to-ship genome-wide human cDNA ORFs on adenoviral or lentiviral vectors, AAV shRNA constructs, pre-made control GFP viruses, AAV biosensors developed in partnership with Janelia Research Campus, AAV alpha-synuclein vectors developed in partnership with The Michael J Fox Foundation, and many others. Vigene was founded in 2012 by senior scientists with expertise in the fields of virology and gene therapy. It is headquartered at Rockville, Maryland.

Total Funding Amount:

$10.5M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Rockville, Maryland, United States

Founded Date:

2012-01-01

Contact Email:

custsupport(AT)vigenebio.com

Founders:

Zairen Sun

Number of Employees:

101-250

Last Funding Date:

2020-03-23

IPO Status:

Private

Industries:

© 2025 bioDAO.ai